Results 21 to 30 of about 2,389,723 (301)

Comparison of antivascular endothelial growth factor treatment for myopia choroidal neovascularisation: a systematic review and meta-analysis of randomised controlled trials

BMJ Open, 2023
Objectives To evaluate the efficacy and safety of anti-vascular endothelial growth factor (anti-VEGF) therapy for myopia choroidal neovascularisation (CNV), and to compare the efficacy of two different anti-VEGF retreatment criteria.Data sources PubMed ...
Chao Zhang, Jie Bai, Liming Dong, Xiao Cheng, Zhihui Song, Guangyao Li   +5 more
doaj   +1 more source

Retrospective Analysis of Treatment Patterns in Pseudophakic Diabetic Macular Oedema Eyes Treated with Anti-VEGF

Journal of Ophthalmology, 2021
Background/Objectives. Currently, in England, antivascular endothelial growth factor (anti-VEGF) is the first-line treatment for diabetic macular oedema (DMO) where central macular thickness (CMT) is ≥400 microns.
Di Zou, Imran Jawaid, Winfried M. Amoaku
doaj   +1 more source

VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy

Annals of Medicine, 2022
Diabetic retinopathy (DR) is the most common microangiopathic complication of diabetes mellitus, representing a major cause of visual impairment in developed countries.
Alessandro Arrigo, Emanuela Aragona, Francesco Bandello   +2 more
doaj   +1 more source

Changes in complement activation products after anti-VEGF injection for choroidal neovascularization in age-related macular degeneration and pachychoroid disease

Scientific Reports, 2021
We evaluated changes in the complement system resulting from anti-vascular endothelial growth factor (VEGF) in eyes with age-related choroidal neovascularization (CNV) including neovascular age-related macular degeneration, pachychoroid neovasculopathy ...
Keiichiro Tanaka, Yasuharu Oguchi, Tomoko Omori, Yumi Ishida, Hiroaki Shintake, Ryutaro Tomita, Akihito Kasai, Masashi Ogasawara, Yukinori Sugano, Kanako Itagaki, Akira Ojima, Takeshi Machida, Hideharu Sekine, Tetsuju Sekiryu   +13 more
doaj   +1 more source

Expert Panel Consensus for Addressing Anti-VEGF Treatment Challenges of Diabetic Macular Edema in Spain [PDF]

, 2022
PURPOSE: The treatment of diabetic macular edema (DME) has evolved rapidly in the past decade, highlighting the need to address the challenges of routine clinical practice decision-making through expert consensus agreements.
Flores-Moreno, Ignacio, Moreno, Luis, Arrevola-Velasco, Luis, Beckford, Carlos, Cobo-Soriano, Rosario, Contreras, Inés, Fernández-Vigo, José Ignacio, Pareja, Jesús, Crespo, María José, Cobo Soriano, Rosario, Ignacio Fernandez-Vigo, Jose, Martín, María Dolores   +11 more
core   +1 more source

Biomarkers as Predictive Factors of Anti-VEGF Response [PDF]

, 2022
Age-related macular degeneration is the main cause of irreversible vision in developed countries, and intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections are the current gold standard treatment today.
Bobadilla, Miriam, Larráyoz, Ignacio M. [0000-0003-1629-152X], Rafael Peláez, Bobadilla, Miriam [0000-0002-7719-3483], Álvaro Pérez-Sala, Larráyoz, Ignacio M., Ana I. Oca, Miriam Bobadilla, Peláez, Rafael [0000-0002-4047-6017], Ana Pariente, Ignacio M. Larráyoz, Oca, Ana I., Peláez, Rafael, Pérez-Sala, Álvaro, Pariente, Ana   +14 more
core   +1 more source

Anti VEGF for post op CME- Boon or Bane!

TNOA Journal of Ophthalmic Science and Research, 2022
Cataract surgery has advanced in techniques and instrumentation over the years, but complications such as cystoid macular edema (CME) do occur even after uneventful surgery.
Roshni Mohan, M Arthi, S Balamurugan
doaj   +1 more source

Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivo

Scientific Reports, 2021
The vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) axis is an essential regulator of angiogenesis and important therapeutic target in cancer.
Tetsuo Mashima, Takeru Wakatsuki, Naomi Kawata, Myung-Kyu Jang, Akiko Nagamori, Haruka Yoshida, Kenichi Nakamura, Toshiro Migita, Hiroyuki Seimiya, Kensei Yamaguchi   +9 more
doaj   +1 more source

The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study

Frontiers in Oncology, 2021
BackgroundIn recent years, immune checkpoint inhibitors (ICIs) in combination with chemotherapy have increased survival in patients with advanced non-small cell lung cancer (NSCLC).
Keiko Tanimura, Tadaaki Yamada, Ayaka Omura, Shinsuke Shiotsu, Nobutaka Kataoka, Takayuki Takeda, Ryusuke Taniguchi, Takahiro Yamada, Mayumi Takeuchi, Yusuke Chihara, Yoshie Morimoto, Masahiro Iwasaku, Yoshiko Kaneko, Junji Uchino, Koichi Takayama   +14 more
doaj   +1 more source

Immunoreactivity of the anti-VEGF-A121 and anti-VEGF-A165 monoclonal antibodies.

, 2023
Mixture of rhVEGF-A121, rhVEGF-A165 and rhVEGF-A189 (50 μg each) were subjected to 15% SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE). The transferred membrane was detected with anti-VEGF-A polyclonal antibody (left panel), anti-VEGF-A165 monoclonal ...
Yoko Oyama (600027), Aryal Bibek (15198524), Taiji Sakamoto (104961), Kazunori Takenouchi (15198521), Kazuhiko Higurashi (15198527), Shingo Yamada (339487), Hideaki Kanda (15198539), Akito Tabaru (15198530), Sadayuki Higashi (15198533), Hiroto Terasaki (104937), Chieko Fujisaki (15198536), Keiichi Inoue (466261), Masashi Okawa (8951294), Kiyonori Tanoue (14928179), Yoshiharu Soga (13883911), Munekazu Yamakuchi (220194), Teruto Hashiguchi (464609)   +16 more
core   +1 more source